Wird geladen...
KRAS G12C inhibition and innate immune targeting
INTRODUCTION: KRAS mutations drive tumorigenesis by altering cell signaling and the tumor immune microenvironment. Recent studies have shown promise for KRAS-G12C covalent inhibitors, which are advancing rapidly through clinical trials. The sequencing and combination of these agents with other thera...
Gespeichert in:
| Veröffentlicht in: | Expert Opin Ther Targets |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8122058/ https://ncbi.nlm.nih.gov/pubmed/33703985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728222.2021.1902991 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|